BioTuesdays

Category - Markets

Angion-Logo
Markets

Stifel starts Angion Biomedica at buy; PT $40

Stifel launched coverage of Angion Biomedica (NASDAQ:ANGN) with a “buy” rating and $40 price target. The stock closed at $19.92 on March 1. Angion’s lead asset, ANG-3777, is a mimetic of hepatocyte growth factor (HGF)...

March 2, 2021
Pharvaris-Logo
Markets

SVB Leerink starts Pharvaris at OP; PT $50

SVB Leerink initiated coverage of Pharvaris B.V. (NASDAQ:PHVS) with an “outperform” rating and $50 price target. The stock closed at $39.23 on March 1. Pharvaris is developing therapies for rare diseases, with a focus...

March 2, 2021
Avita Medical
Markets

Piper starts Avita Medical at OW; PT $27

Piper Sandler launched coverage of Avita Medical (NASDAQ:RCEL) with an “overweight” rating and $27 price target. The stock closed at $21.49 on March 1. Avita makes Recell, which uses a patient’s own skin to make a cell...

March 2, 2021
Lucira-Health-Logo
Markets

WB starts Lucira Health at OP

William Blair initiated coverage of Lucira Health (NASDAQ:LHDX) with an “outperform” rating, based on “our outlook for a series of positive catalysts on commercialization and manufacturing as well as what we believe is...

March 2, 2021
Evaxion-Al-Immunology
Markets

Ladenburg starts Evaxion Biotech at buy; PT $23

Ladenburg Thalmann initiated coverage of Evaxion Biotech A/S (NASDAQ:EVAX) with a “buy” rating and $23 price target. The stock closed at $7.08 on March 1. Evaxion is a clinical-stage artificial intelligence (AI)...

March 2, 2021
Sensus Healthcare Logo
Markets

AGP ups Sensus Healthcare PT to $7.50 from $2.95

Alliance Global Partners raised its price target for Sensus Healthcare (NASDAQ:SRTS) to $7.50 from $2.95, citing fourth quarter results that were well ahead of consensus estimates. The stock closed at $4.94 on March 1...

March 2, 2021
Markets

Cantor starts DarioHealth at OW; PT $35

Cantor Fitzgerald launched coverage of DarioHealth (NASDAQ:DRIO) with an “overweight” rating and price target of $35. The stock closed at $29.16 on Feb. 24. Dario is a digital health company that is developing and...

February 25, 2021
Lensar
Markets

SVB Leerink starts Lensar at OP; PT $20

SVB Leerink initiated coverage of Lensar (NASDAQ:LNSR) with an “outperform” rating and price target of $20. The stock closed at $9.50 on Feb. 23. Lensar was recently spun out from PDL Biopharma and is, “in our view, an...

February 24, 2021